Please fill out the form below and we will gladly respond as soon as possible.
Synovial sarcoma most often develops near the large joints of the arms or legs, but in rare cases it can arise in the head and neck region. An especially uncommon presentation occurs in infants. A recently published case report describes synovial sarcoma originating in the parotid gland—the salivary gland located near the jaw and ear—in […]
Content Warning:This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care. Synovial sarcoma most often develops in the extremities, but in rare cases, it can […]
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for ZI-MA4-1 (ZIMA-101), a first-in-human cell therapy study that will include patients with synovial sarcoma. While this trial is still in its earliest phase, it represents a notable scientific development for the synovial sarcoma community. What […]
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the state to receive a cutting-edge immune-cell therapy, TECELRA, at the HonorHealth Research Institute in Scottsdale. Synovial sarcoma is a rare soft-tissue cancer that primarily affects large joints in the arms and legs, though it can […]
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive fibroblast that still carries embryonic markers (Hic1⁺ Pdgfra⁺ Lgr5⁺). Breaking 2025 Research: Read the entire article here. Learn more about our world-renowned registry efforts here.
Not every detected cancer is clinically meaningful. For younger patients, especially, this can mean confronting a diagnosis that may never progress but still carries psychological and treatment burdens.
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]